Erdafitinib-associated retinal alterations and rapid onset bilateral white cataracts
Purpose: This report aims to highlight the wide spectrum of ophthalmic adverse events associated with erdafitinib, a fibroblast growth factor inhibitor that blocks activation of the mitogen-activated protein kinase kinase (MAPK/MEK) cascade. The purpose of this report is to describe a case of erdafi...
Main Authors: | Antoine G. Sassine, Yavuz Cakir, Lyndsey Della Vecchia, Justis P. Ehlers |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-06-01
|
Series: | American Journal of Ophthalmology Case Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2451993624000380 |
Similar Items
-
Severe onycholysis and eyelash trichomegaly in a patient treated with erdafitinib
by: Alana Deutsch, BA, et al.
Published: (2020-06-01) -
Erdafitinib treatment in metastatic urothelial carcinoma: a real-world analysis
by: Keren Rouvinov, et al.
Published: (2023-05-01) -
Erdafitinib Antagonizes ABCB1-Mediated Multidrug Resistance in Cancer Cells
by: Weiguo Feng, et al.
Published: (2020-06-01) -
Adverse events in patients with advanced urothelial carcinoma treated with erdafitinib: a retrospective pharmacovigilance study
by: Tengfei Yuan, et al.
Published: (2023-11-01) -
Identifying fibroblast growth factor receptor genetic alterations using RNA‐based assays in patients with metastatic or locally advanced, surgically unresectable, urothelial carcinoma who may benefit from erdafitinib treatment
by: Songbai Wang, et al.
Published: (2020-07-01)